Clinical Trials Browser

Phase 1 × Lymphoma × Nivolumab × Clear all

NCT03502733 2026-03-18

Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma

Phase 1 Active not recruiting

64 enrolled

Lymphoid

Lymphoma, Neoplasm Metastasis

NCT04022980 2025-12-30

Nivolumab Consolidation in Older (≥ 65) Patients With Primary CNS Lymphoma

Phase 1 Completed

14 enrolled

Lymphoid

Lymphoma, Neurologic Manifestations

NCT03229278 2023-12-06

Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma

Phase 1 Completed

14 enrolled 13 charts

DermatologicGenitourinaryHead & NeckLymphoidThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Lymphoma, Melanoma, Neoplasm Metastasis

NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Phase 1 Completed

37 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT03588936 2021-10-11

Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant

Phase 1 Terminated

2 enrolled

LymphoidMyeloid

Lymphoma, Myelodysplastic Syndromes

NCT02518958 2019-11-18

PRIMETIME

Phase 1 Completed

12 enrolled

Lymphoid

Lymphoma